A SPAC II identifies Taiwan medtech target for potential business combination

ASPAC II Acquisition Corp.

Target specializes in microsphere tech for ultrasound contrast agents and drug delivery.
First product has passed review to enter Phase 3 trial application with USFDA.
Special meeting on Aug 1, 2023 to vote on extension and other proposals.
Company in preliminary talks to enter non-binding LOI with Partner.
No guarantee definitive agreement will be reached; due diligence ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.